Heron Therapeutics gains on pact to expand sales network for pain relief drug

Heron Therapeutics

08/01/2024 11:13

** Drugmaker Heron Therapeutics'  HRTX.O  shares up about
16.4% at $2.10 premarket
    ** Company on Sunday entered into a five-year distributor
partnership with CrossLink Life Sciences to expand sales network
for its local anesthetic Zynrelef
    ** CrossLink will be compensated on a fixed-fee per vial
basis, based on growth over a pre-determined baseline period,
according to the terms
    ** CrossLink will be the lead partner in the U.S. to expand
the drug's promotion for orthopedic indications
    ** CrossLink is a private orthopedic, spine and sports
medicine device distributorship in the United States
    ** In total, about 650 representatives will be added to
Heron's sales network over the next year - company
    ** Zynrelef is a non-opioid drug currently approved to treat
pain following foot and ankle, joint replacement and some open
abdominal surgeries
    ** U.S. FDA is set to make a decision on expanded use of the
drug in soft tissue and orthopedic surgical procedures, later
this month 
    ** HRTX stock fell 32% in 2023

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))